Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

NCT00242918 ·Status: COMPLETED ·Phase: PHASE2

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00483561 ·Status: TERMINATED ·Phase: PHASE2

Trastuzumab in Treating Patients With Prostate Cancer

NCT00003740 ·Status: COMPLETED ·Phase: PHASE2

Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer

NCT05557604 ·Status: RECRUITING ·Phase: PHASE2

Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer

NCT06236789 ·Status: RECRUITING

A Long Term Safety Study With Atrasentan

NCT00127478 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

NCT01663415 ·Status: WITHDRAWN ·Phase: PHASE2

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

NCT00055471 ·Status: COMPLETED ·Phase: PHASE2

Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)

NCT01118741 ·Status: COMPLETED ·Phase: NA

R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005848 ·Status: COMPLETED ·Phase: PHASE2

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

NCT03471650 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

NCT00510718 ·Status: COMPLETED ·Phase: PHASE1

Mifepristone (RU-486) in Androgen Independent Prostate Cancer

NCT00140478 ·Status: COMPLETED ·Phase: PHASE2

A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy

NCT01302041 ·Status: COMPLETED ·Phase: PHASE2

Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer

NCT00427999 ·Status: COMPLETED ·Phase: PHASE2

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

NCT00278993 ·Status: COMPLETED ·Phase: PHASE2

A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer

NCT00564928 ·Status: COMPLETED ·Phase: PHASE2

Phase II Study of ASP3550 in Patients With Prostate Cancer

NCT00568516 ·Status: COMPLETED ·Phase: PHASE2

Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer

NCT01787331 ·Status: COMPLETED ·Phase: PHASE2

Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer

NCT00319787 ·Status: COMPLETED ·Phase: PHASE2

A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer

NCT01964170 ·Status: COMPLETED ·Phase: PHASE3

To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients

NCT03017313 ·Status: COMPLETED

Study to Find Maintenance Dose for Periodic Administration of ASP3550

NCT01261572 ·Status: COMPLETED ·Phase: PHASE2

Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer

NCT00115635 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

NCT01534052 ·Status: COMPLETED ·Phase: PHASE2